Thought Leadership
FDA Extends Enforcement Discretion Period for Regenerative Medicine Products, but This Isn't a Green Light for Bad Actors
August 6, 2020
Chad Landmon
Cell & Gene

Axinn partner Chad Landmon co-authored the Cell & Gene article, "FDA Extends Enforcement Discretion Period for Regenerative Medicine Products, but This Isn't a Green Light for Bad Actors."

Click here to access the article.

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.